Extending The MIS BAIR Randomised Trial Of BCG To Prevent Childhood Allergy And Infection
Funder
National Health and Medical Research Council
Funding Amount
$939,504.00
Summary
BCG (used till recently to prevent tuberculosis) is a potential low cost and readily available vaccine which could reduce the rates of allergy and infection in Australian children. We propose to extend our existing NHMRC-funded trial, which studies whether BCG vaccinatinon given at birth prevents the development food allergy, eczema and infection in the 1st year of life, to see if this effect continues until 5yrs of age. At this age, we can also see if BCG vaccination at birth prevents asthma.
Investigation Into Host Susceptibility And Immune Responses In Young Children With Acute Wheezing Due To Human Rhinovirus Group C Infection
Funder
National Health and Medical Research Council
Funding Amount
$682,711.00
Summary
We recently made the surprising discovery that a new viral group, human rhinovirus group C (HRV-C), causes the majority of acute asthma in children. We also found that it causes half of the acute wheezing attacks in younger children, and is the only respiratory virus associated with allergy. So, HRV-C may be the key to the relationship between allergy and asthma. The planned project will focus on whether young children who wheeze with HRV-C have related defects in their immune system.
Improving Breathing Support For Newborn Infants In Non-Tertiary Centres: The HUNTER Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,203,844.00
Summary
Every year in Australia, thousands of newborn babies have breathing difficulties. Our trial will study a new, simple method of providing breathing support to newborn babies in special care nurseries, called high-flow (HF). HF is cheaper, easier to use, and more comfortable for babies than the current standard treatment, called CPAP. If HF is as good as CPAP at supporting babies' breathing, it will change practice in Australia and around the world.
High Flow Cannula Therapy In Bronchiolitis, A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,283,342.00
Summary
Bronchiolitis is the leading cause of paediatric hospitalisation in Australia. Despite multiple research studies the outcome has not changed. Our recent studies supported by other international studies have shown that the use of high flow nasal cannula oxygen may reduce the severity and prevent progression of the disease. We aim to investigate if HFNC in regional hospitals can reduce the number of infants transferred to specialist children’s hospitals and reduce the socio-economic burden.
A POPULATION-BASED COHORT INVESTIGATION OF LUNG FUNCTION IN RELATION TO EARLY LIFE LOWER RESPIRATORY TRACT ILLNESS AND AEROALLERGN SENSITISATION
Funder
National Health and Medical Research Council
Funding Amount
$456,013.00
Summary
Infancy appears to be the critical developmental window during which important alterations in lung structure and function develop. In this study we will assess how early lung function evolves in relation to potential insults such as lower respiratory tract infections and allergic inflammation. These are the mechanisms by which asthma is thought to develop. We will use exciting new lung function tests to evaluate lung function abnormalities associated with peripheral dysfunction characteristic of ....Infancy appears to be the critical developmental window during which important alterations in lung structure and function develop. In this study we will assess how early lung function evolves in relation to potential insults such as lower respiratory tract infections and allergic inflammation. These are the mechanisms by which asthma is thought to develop. We will use exciting new lung function tests to evaluate lung function abnormalities associated with peripheral dysfunction characteristic of chronic airway disease such as asthma.Read moreRead less
A Randomised Controlled Trial To Evaluate Early Intervention In Chronic Cough In Indigenous Children
Funder
National Health and Medical Research Council
Funding Amount
$1,432,252.00
Summary
This study aims to determine whether a validated evidence-based cough algorithm initiated at the development of chronic cough, defined as >4 weeks duration, following an acute respiratory illness (ARI) improves clinical outcomes in urban, rural and remote Indigenous children compared to standard care. The study will also examine the predictors of chronic cough and cough outcomes in these children as well as the cost-effectivess of the intervention.
Nasal Highflow For Paediatric Acute Hypoxic Respiratory Failure
Funder
National Health and Medical Research Council
Funding Amount
$2,627,819.00
Summary
The burden of respiratory disease in children requiring intensive care admission is increasing despite better quality care in hospitals. This study investigates a new method, called nasal high flow, to support the breathing of children, that can be provided in regular children's wards in regional and metropolitan hospitals. The study anticipates to demonstrate that early intervention with nasal high flow reduces the need for intensive care admission.
Amniotic Exosomes - Nanomedicine For Bronchopulmonary Dysplasia
Funder
National Health and Medical Research Council
Funding Amount
$647,058.00
Summary
Extremely premature babies are at serious risk of developing a life threatening chronic lung disease known as bronchopulmonary dysplasia. This is expensive to treat and even babies who survive often end up with lifelong complications. Our team believes that nanoparticles released by placental stem cells have the ability to reverse the disease and that this can be administered without complex medical tools so that parents can administer it themselves after discharge.
Human Amnion Epithelial Cell Therapy For Bronchopulmonary Dyspliasa
Funder
National Health and Medical Research Council
Funding Amount
$1,048,035.00
Summary
Preterm infants, especially those born very early, commonly develop a type of chronic lung disease called bronchopulmonary displasia (BPD). There is currently no cure or means of preventing BPD. Cells from the amniotic membrane that surrounds the developing baby before birth show promise as a treatment, or perhaps even a way of preventing, BPD. This project will use a preterm lamb model of BPD to assess the ability of amnion cells to treat or prevent the disease.
Optimising Early Respiratory Support For Preterm Infants: The HIPSTER Trial
Funder
National Health and Medical Research Council
Funding Amount
$696,791.00
Summary
Premature babies who need breathing support are often given ‘nasal continuous positive airway pressure’ (NCPAP) via large nasal prongs. It works well but is uncomfortable. A newer, popular support is ‘high flow’ (HF) which uses smaller nose prongs and may be more comfortable, but HF has not been well studied. The HIPSTER trial will compare these systems in 750 premature babies, at random half will have NCPAP, half will have HF. We will assess whether babies do equally well with each system.